WVE (Wave Life Sciences) Growth Rank: 8 (As of Sep. 06, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WVE Wave Life Sciences Inc WVE
60 GF Score
Price $4.85
GF Value $3.88
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Wave Life Sciences Growth Rank?

Wave Life Sciences WVE +3.29% 60 Growth Rank is 8 as of Sep. 06, 2026, which is 100% above its 10-year median of 4.00. GuruFocus rates WVE with a GF Score™ of 60/100 and a GF Value™ of $3.88 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Wave Life Sciences has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Wave Life Sciences Growth Rank Related Terms

WVE vs IMMX, CADL, ARDX: Growth Rank Comparison

For the Biotechnology subindustry, Wave Life Sciences's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wave Life Sciences Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wave Life Sciences's Growth Rank distribution charts can be found below:

* The bar in red indicates where Wave Life Sciences's Growth Rank falls into.


WVE
60GF Score
Wave Life Sciences Inc WVE
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
Wave Life Sciences (WVE) has a Growth Rank of 8 as of Sep. 06, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Wave Life Sciences and its competitors. This is 100% above median its historical median of 4.00. Over the past decade, Wave Life Sciences' Growth Rank has ranged from 2.00 to 10.00.
Is Wave Life Sciences' Growth Rank too high?
Wave Life Sciences' current Growth Rank of 8 is 100% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Wave Life Sciences has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' Growth Rank compare to IMMX and CADL?
Wave Life Sciences' Growth Rank of 8 can be compared against companies in the Biotechnology industry. Historically, Wave Life Sciences' own Growth Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Wave Life Sciences and its competitors. Wave Life Sciences's current Growth Rank is 8, which is 100% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.88, compared to a current price of $4.85 — trading 25% above its estimated fair value. The current Growth Rank is 8, which is 100% above median its 10-year median of 4.00. Wave Life Sciences' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current Growth Rank is 8 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wave Life Sciences (WVE) Overvalued in 2026?

Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued. The current stock price of $4.85 is trading 25% above its estimated GF Value™ of $3.88. GuruFocus considers Wave Life Sciences to be Modestly Overvalued.

Key valuation signals for WVE:

  • Growth Rank: 8 (100% above median its 10-year median of 4.00)
  • GF Value™: $3.88 vs. price of $4.85 (25% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wave Life Sciences Business Description

Other Exchanges 1U5:Germany
Address 7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
60GF Score

Get the complete analysis for WVE

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.85
Price
$3.88
GF Value